Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation

  • Nat Chem Biol. 2015 May;11(5):339-46. doi: 10.1038/nchembio.1788.
Li Li  1 Yuan Liu  1 Hang-zi Chen  1 Feng-wei Li  1 Jian-feng Wu  1 Hong-kui Zhang  2 Jian-ping He  1 Yong-zhen Xing  1 Yan Chen  1 Wei-jia Wang  1 Xu-yang Tian  1 An-zhong Li  1 Qian Zhang  1 Pei-qiang Huang  2 Jiahuai Han  1 Tianwei Lin  1 Qiao Wu  1
Affiliations
  • 1. State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs from Natural Products, School of Life Sciences, Xiamen University, Xiamen, Fujian Province, China.
  • 2. Key Laboratory for Chemical Biology of Fujian Province, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian Province, China.
Abstract

Sepsis, a hyperinflammatory response that can result in multiple organ dysfunctions, is a leading cause of mortality from Infection. Here, we show that Orphan Nuclear Receptor Nur77 (also known as TR3) can enhance resistance to lipopolysaccharide (LPS)-induced sepsis in mice by inhibiting NF-κB activity and suppressing aberrant cytokine production. Nur77 directly associates with p65 to block its binding to the κB element. However, this function of Nur77 is countered by the LPS-activated p38α phosphorylation of Nur77. Dampening the interaction between Nur77 and p38α would favor Nur77 suppression of the hyperinflammatory response. A compound, n-pentyl 2-[3,5-dihydroxy-2-(1-nonanoyl) phenyl]acetate, screened from a Nur77-biased library, blocked the Nur77-p38α interaction by targeting the ligand-binding domain of Nur77 and restored the suppression of the hyperinflammatory response through Nur77 inhibition of NF-κB. This study associates the nuclear receptor with immune homeostasis and implicates a new therapeutic strategy to treat hyperinflammatory responses by targeting a p38α substrate to modulate p38α-regulated functions.

Products